God, AIDS, Africa & HOPE

pensées of a Catholic priest

Risk of AIDS, Serious Illness and Death Reduced by 53% with Early ART

Press Release of the National Institute of Allergy and Infectious Diseases ( US Department of Health and Human Services)

Starting Antiretroviral Treatment Early Improves Outcomes for HIV-Infected Individuals
A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count—a key measure of immune system health—is higher, instead of waiting until the CD4+ cell count drops to lower levels. Together with data from previous studies showing that antiretroviral treatment reduced the risk of HIV transmission to uninfected sexual partners, these findings support offering treatment to everyone with HIV.
The new finding is from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to establish that earlier antiretroviral treatment benefits all HIV-infected individuals. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, provided primary funding for the START trial. Though the study was expected to conclude at the end of 2016, an interim review of the study data by an independent data and safety monitoring board (DSMB) recommended that results be released early.
“We now have clear-cut proof that it is of significantly greater health benefit to an HIV-infected person to start antiretroviral therapy sooner rather than later,” said NIAID Director Anthony S. Fauci, M.D. “Moreover, early therapy conveys a double benefit, not only improving the health of individuals but at the same time, by lowering their viral load, reducing the risk they will transmit HIV to others. These findings have global implications for the treatment of HIV.”
“This is an important milestone in HIV research,” said Jens Lundgren, M.D., of the University of Copenhagen and one of the co-chairs of the START study. “We now have strong evidence that early treatment is beneficial to the HIV-positive person. These results support treating everyone irrespective of CD4+ T-cell count.”
The START study, which opened widely in March 2011, was conducted by the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) at 215 sites in 35 countries. The trial enrolled 4,685 HIV-infected men and women ages 18 and older, with a median age of 36. Participants had never taken antiretroviral therapy and were enrolled with CD4+ cell counts in the normal range—above 500 cells per cubic millimeter (cells/mm3). Approximately half of the study participants were randomized to initiate antiretroviral treatment immediately (early treatment), and the other half were randomized to defer treatment until their CD4+ cell count declined to 350 cells/mm3. On average, participants in the study were followed for three years.
The study measured a combination of outcomes that included serious AIDS events (such as AIDS-related cancer), serious non-AIDS events (major cardiovascular, renal and liver disease and cancer), and death. Based on data from March 2015, the DSMB found 41 instances of AIDS, serious non-AIDS events or death among those enrolled in the study’s early treatment group compared to 86 events in the deferred treatment group. The DSMB’s interim analysis found risk of developing serious illness or death was reduced by 53 percent among those in the early treatment group, compared to those in the deferred group.
Rates of serious AIDS-related events and serious non-AIDS-related events were both lower in the early treatment group than the deferred treatment group. The risk reduction was more pronounced for the AIDS-related events. Findings were consistent across geographic regions, and the benefits of early treatment were similar for participants from low- and middle-income countries and participants from high-income countries.
“The study was rigorous and the results are clear,” said INSIGHT principal investigator James D. Neaton, Ph.D., a professor of biostatistics at the University of Minnesota, Minneapolis. “The definitive findings from a randomized trial like START are likely to influence how care is delivered to millions of HIV-positive individuals around the world.” The University of Minnesota served as the trial’s regulatory sponsor and statistical and data management center.
Prior to the START trial, there was no randomized controlled trial evidence to guide initiating treatment for individuals with higher CD4+ cell counts. Previous evidence to support early treatment among HIV-positive people with CD4+ cell counts above 350 was limited to data from non-randomized trials or observational cohort studies, and on expert opinion.
START is the first large-scale randomized clinical trial to offer concrete scientific evidence to support the current U.S. HIV treatment guidelines, which recommend that all asymptomatic HIV-infected individuals take antiretrovirals, regardless of CD4+ cell count. Current World Health Organization HIV treatment guidelines recommend that HIV-infected individuals begin antiretroviral therapy when CD4+ cell counts fall to 500 cells/mm3 or less.
In light of the DSMB findings, study investigators are informing all participants of the interim results. Participants will be offered treatment if they are not already on antiretroviral therapy, and they will continue to be followed through 2016.
The HIV medicines used in the trial are approved medications donated by AbbVie, Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, LLC, and Merck Sharp & Dohme Corp.
In addition to NIAID, funding for the START trial came from other NIH entities, including the National Cancer Institute; the National Heart, Lung and Blood Institute; the National Institute of Mental Health; the National Institute of Neurological Disorders and Stroke; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the NIH Clinical Center; and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Funding was also provided by the National Agency for Research on AIDS and Viral Hepatitis (ANRS) in France, the Federal Ministry of Education and Research in Germany, the European AIDS Treatment Network and government organizations based in Australia, Denmark, and the United Kingdom.
The Medical Research Council Clinical Trials Unit at University College London; the Copenhagen HIV Program at the Rigshospitalet, University of Copenhagen in Denmark; the Kirby Institute at the University of New South Wales in Sydney, Australia; and the Veterans Affairs Medical Center affiliated with George Washington University in Washington, D.C. coordinated the work of the 215 START sites.
For more information about the START trial, see the Questions and Answers or visit ClinicalTrials.gov using study identifier NCT00867048.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health ®

 

Filed under: HIV and AIDS, HIV Prevention, HIV Treatment, Medical and Research, Networking, , , , , , , , , ,

No time to rest in the fight against HIV and AIDS

Coming back from Europe and heading next week to the World Aids Conference in Melbourne, the news about the so-called “Mississippi Baby” feels like a punch in the gut and a damper to the hopes of a functional cure. The child known as the “Mississippi baby” — whose apparent cure was reported in The New England Journal of Medicine last fall — has had the virus return after more than two years off anti-retroviral therapy, according to specialists involved in the case who spoke in a Thursday news briefing. “Certainly, this is a disappointing turn of events for this young child, the medical staff involved in the child’s care and the HIV/AIDS research community,” said Anthony Fauci, director of the National Institute of Allergy and Infection Diseases (USA), at the briefing. The development “reminds us that we still have much more to learn about the intricacies of HIV infection and where the virus hides in the body,” Fauci said in a statement. “The NIH remains committed to moving forward with research on a cure for HIV infection.”
Not only the NIH, but we all, the activists, researchers and those infected and affected have to acknowledge how bumpy the road to a functional cure or even a vaccine will be. This story ones again reminds us that HIV and Aids are not defeated yet. The easiness of European youth and society in believing that some pills would sort out those being infected – and further believing that this anyhow only applies to those others, those being gay or immigrants from Africa or injecting drug users should be re-evaluated after such news. HIV and Aids are still a treat to humanity and society and as we make progress, we can’t declare victory. Otherwise we look as stupid as then-president Bush declaring victory over Iraq on one of his war ships – look at the situation in the country in our days.
The news about the Mississippi baby should also serve as a warning to donors that withdrawing funding because we have won the battle is an illusion. The Global Aids Fund and all the NGO’s in the field of HIV, Aids and related illnesses need more funding to gain progress in the fight against the syndrome. We have achieved so much but there are still millions dying every year as a result of the pandemic and there are millions out there without treatment. Resistance is growing and we only have to look at TB and South Africa to see what could develop if we not keep watch. The virus is waiting for a re-run if society is not taking it serious anymore. And the dream of a HIV free generation will be blown up in shatters – therefore no time to rest in the fight against HIV and Aids.

Filed under: HIV and AIDS, HIV Prevention, HIV Treatment, Medical and Research, Politics and Society, Reflection, , , , , , , , , , , , , , , , , , , , , , , ,

Blog Categories

Follow God, AIDS, Africa & HOPE on WordPress.com

15th HOPE Gala Dresden

HOPE Gala Dresden - the event to be in DresdenOctober 31st, 2020
2 days to go.

Ball of HOPE 2021

Join us @ The Westin in Cape TownMay 15th, 2021
6 months to go.

Stefan Hippler Twitter Account

  • RT @pierredevos: It’s not so much that Trump is lying more as that the lies have become qualitatively different — even more blatant, and in… - 2 hours ago

You can share this blog in many ways..

Bookmark and Share

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 3,076 other followers

Translation – Deutsch? Française? Espanol? …

The translation button is located on each single blog page, Copy the text, click the button and paste it for instant translation:
Website Translation Widget

or for the translation of the front page:

* Click for Translation

Copyright

© Rev Fr Stefan Hippler and HIV, AIDS and HOPE.
Unauthorized use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Rev Fr Stefan Hippler and HIV, AIDS and HOPE with appropriate and specific direction to the original content.

This not withstanding the following applies:
Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 3.0 Unported License.

%d bloggers like this: